{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:35Z","timestamp":1786975595120,"version":"build-2736575974"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamadermatol.2020.2240","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T22:58:31Z","timestamp":1597273111000},"page":"1066","source":"Crossref","is-referenced-by-count":43,"title":["Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis"],"prefix":"10.1001","volume":"156","author":[{"given":"Maryam M.","family":"Asgari","sequence":"first","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"Department of Population Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Lin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay","family":"Avalos","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sokil","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles P.","family":"Quesenberry","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"doi200043r1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis.","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"doi200043r2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5021\/ad.2012.24.3.253","article-title":"Long term treatment concepts and proactive therapy for atopic eczema.","volume":"24","author":"Wollenberg","year":"2012","journal-title":"Ann Dermatol"},{"issue":"4","key":"doi200043r3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00008480-200208000-00010","article-title":"Topical immunomodulators for atopic dermatitis.","volume":"14","author":"Bernard","year":"2002","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"doi200043r4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000086739","article-title":"Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.","volume":"211","author":"Hultsch","year":"2005","journal-title":"Dermatology"},{"issue":"10","key":"doi200043r5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012.","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"doi200043r6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.146.s61.2.x","article-title":"The epidemiology of skin cancer.","volume":"146","author":"Diepgen","year":"2002","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi200043r7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2008.01.009","article-title":"Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D.","volume":"261","author":"Oberyszyn","year":"2008","journal-title":"Cancer Lett"},{"issue":"9","key":"doi200043r8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1001\/jamadermatol.2015.1188","article-title":"Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012.","volume":"151","author":"Asgari","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi200043r9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.125579","article-title":"Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management.","volume":"47","author":"Berg","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi200043r10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaci.2005.04.006","article-title":"Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.","volume":"115","author":"Fonacier","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi200043r11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00002018-200831030-00001","article-title":"The US FDA \u201cblack box\u201d warning for topical calcineurin inhibitors: an ongoing controversy.","volume":"31","author":"Ring","year":"2008","journal-title":"Drug Saf"},{"issue":"3","key":"doi200043r12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/09546630510041088","article-title":"Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus.","volume":"16","author":"Naylor","year":"2005","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi200043r13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2133.2005.06899.x","article-title":"Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?","volume":"153","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi200043r14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaad.2006.01.054","article-title":"The use of topical calcineurin inhibitors in dermatology: safety concerns: report of the American Academy of Dermatology Association Task Force.","volume":"54","author":"Berger","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi200043r15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000100879","article-title":"Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.","volume":"214","author":"Margolis","year":"2007","journal-title":"Dermatology"},{"issue":"6","key":"doi200043r16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamadermatol.2014.4305","article-title":"Association between malignancy and topical use of pimecrolimus.","volume":"151","author":"Margolis","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi200043r17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/09546634.2016.1163317","article-title":"Topical calcineurin inhibitors in eczema and cancer association: a cohort study.","volume":"27","author":"Cai","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"doi200043r18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CLEP.S146442","article-title":"A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation\u2014JOELLE study).","volume":"10","author":"Castellsague","year":"2018","journal-title":"Clin Epidemiol"},{"key":"doi200043r20","first-page":"225","article-title":"Automatic SNOMED coding.","author":"Moore","year":"1994","journal-title":"Proc Annu Symp Comput Appl Med Care"},{"issue":"9","key":"doi200043r21","first-page":"944","article-title":"SNOMED-encoded surgical pathology databases: a tool for epidemiologic investigation.","volume":"9","author":"Berman","year":"1996","journal-title":"Mod Pathol"},{"issue":"1","key":"doi200043r22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjd.14423","article-title":"Atopic dermatitis is not associated with actinic keratosis: cross-sectional results from the Rotterdam study.","volume":"175","author":"Hajdarbegovic","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi200043r23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/bjd.14031","article-title":"Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study.","volume":"173","author":"Silverberg","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200043r24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research.","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"doi200043r19","unstructured":"Mylan. Elidel New Zealand data sheet. Accessed December 31, 2019. https:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/e\/Elidelcr.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2768937\/jamadermatology_asgari_2020_oi_200043_1602515675.41934.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T11:45:16Z","timestamp":1602675916000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2768937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.2240","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}